These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37425694)

  • 21. Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease.
    Francisco AF; Jayawardhana S; Taylor MC; Lewis MD; Kelly JM
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prodrugs as new therapies against Chagas disease: in vivo synergy between Trypanosoma cruzi proline racemase inhibitors and benznidazole.
    de Melo GD; Coatnoan N; Gouault N; Cupif JF; Renault J; Cosson A; Uriac P; Blondel A; Minoprio P
    J Glob Antimicrob Resist; 2022 Mar; 28():84-89. PubMed ID: 34929377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolomics, lipidomics and proteomics profiling of myoblasts infected with Trypanosoma cruzi after treatment with different drugs against Chagas disease.
    Hennig K; Abi-Ghanem J; Bunescu A; Meniche X; Biliaut E; Ouattara AD; Lewis MD; Kelly JM; Braillard S; Courtemanche G; Chatelain E; Béquet F
    Metabolomics; 2019 Aug; 15(9):117. PubMed ID: 31440849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parasitemia Levels in Trypanosoma cruzi Infection in Spain, an Area Where the Disease Is Not Endemic: Trends by Different Molecular Approaches.
    Flores-Chavez MD; Abras A; Ballart C; Ibáñez-Perez I; Perez-Gordillo P; Gállego M; Muñoz C; Moure Z; Sulleiro E; Nieto J; García Diez E; Simón L; Cruz I; Picado A
    Microbiol Spectr; 2022 Oct; 10(5):e0262822. PubMed ID: 36190410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in
    Barbosa JMC; Pedra-Rezende Y; Pereira LD; de Melo TG; Barbosa HS; Lannes-Vieira J; de Castro SL; Daliry A; Salomão K
    Front Cell Infect Microbiol; 2022; 12():975931. PubMed ID: 36093188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of a combined treatment with a therapeutic vaccine and benznidazole for the Trypanosoma cruzi chronic infection.
    Prochetto E; Bontempi I; Rodeles L; Cabrera G; Vicco M; Cacik P; Pacini MF; Pérez Gianeselli M; Pérez AR; Marcipar I
    Acta Trop; 2022 May; 229():106334. PubMed ID: 35101415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
    Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
    Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.
    Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA
    Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations.
    Lima DA; Gonçalves LO; Reis-Cunha JL; Guimarães PAS; Ruiz JC; Liarte DB; Murta SMF
    Parasit Vectors; 2023 May; 16(1):167. PubMed ID: 37217925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD8
    Mateus J; Nocua P; Lasso P; López MC; Thomas MC; Egui A; Cuervo C; González JM; Puerta CJ; Cuéllar A
    Front Cell Infect Microbiol; 2021; 11():723121. PubMed ID: 34712620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients.
    Zrein M; Granjon E; Gueyffier L; Caillaudeau J; Liehl P; Pottel H; Cardoso CS; Oliveira CDL; de Oliveira LC; Lee TH; Ferreira AM; Ribeiro ALP; Busch MP; Sabino EC
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006226. PubMed ID: 29425201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
    Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct Treatment Outcomes of Antiparasitic Therapy in
    Albareda MC; Natale MA; De Rissio AM; Fernandez M; Serjan A; Alvarez MG; Cooley G; Shen H; Viotti R; Bua J; Castro Eiro MD; Nuñez M; Fichera LE; Lococo B; Scollo K; Tarleton RL; Laucella SA
    Front Immunol; 2018; 9():1958. PubMed ID: 30271399
    [No Abstract]   [Full Text] [Related]  

  • 35. A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against Trypanosoma cruzi.
    Rodrigues JH; Ueda-Nakamura T; Corrêa AG; Sangi DP; Nakamura CV
    PLoS One; 2014; 9(1):e85706. PubMed ID: 24465654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stress-Induced Proliferation and Cell Cycle Plasticity of Intracellular
    Dumoulin PC; Burleigh BA
    mBio; 2018 Jul; 9(4):. PubMed ID: 29991586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thioridazine aggravates skeletal myositis, systemic and liver inflammation in Trypanosoma cruzi-infected and benznidazole-treated mice.
    Mendonça AAS; Gonçalves-Santos E; Souza-Silva TG; González-Lozano KJ; Caldas IS; Gonçalves RV; Diniz LF; Novaes RD
    Int Immunopharmacol; 2020 Aug; 85():106611. PubMed ID: 32447223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug transporter and oxidative stress gene expression in human macrophages infected with benznidazole-sensitive and naturally benznidazole-resistant Trypanosoma cruzi parasites treated with benznidazole.
    Téllez J; Romero I; Romanha AJ; Steindel M
    Parasit Vectors; 2019 May; 12(1):262. PubMed ID: 31126349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunosuppression and Chagas disease: a management challenge.
    Pinazo MJ; Espinosa G; Cortes-Lletget C; Posada Ede J; Aldasoro E; Oliveira I; Muñoz J; Gállego M; Gascon J
    PLoS Negl Trop Dis; 2013; 7(1):e1965. PubMed ID: 23349998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.